Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

To assess the response rate and the tolerance of irinotecan as first-line therapy, 40 patients with metastatic gastric cancer received irinotecan 350 mg m(−2) every 3 weeks administered as a 30 min infusion. Among the 35 patients evaluable for response, two complete and five partial responses were r...

Descripción completa

Detalles Bibliográficos
Autores principales: Köhne, C-H, Catane, R, Klein, B, Ducreux, M, Thuss-Patience, P, Niederle, N, Gips, M, Preusser, P, Knuth, A, Clemens, M, Bugat, R, Figer, I, Shani, A, Fages, B, Betta, D Di, Jacques, C, Wilke, H J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376958/
https://www.ncbi.nlm.nih.gov/pubmed/12966415
http://dx.doi.org/10.1038/sj.bjc.6601226

Ejemplares similares

Ejemplares similares